Zhang Fang, Sodroski Catherine, Cha Helen, Li Qisheng, Liang T Jake
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Gastroenterology. 2017 Jan;152(1):257-270.e7. doi: 10.1053/j.gastro.2016.09.033. Epub 2016 Sep 30.
BACKGROUND & AIMS: The signaling molecule and transcriptional regulator SMAD6, which inhibits the transforming growth factor β signaling pathway, is required for infection of hepatocytes by hepatitis C virus (HCV). We investigated the mechanisms by which SMAD6 and another inhibitory SMAD (SMAD7) promote HCV infection in human hepatoma cells and hepatocytes.
We infected Huh7 and Huh7.5.1 cells and primary human hepatocytes with Japanese fulminant hepatitis-1 (JFH1) HCV cell culture system (HCVcc). We then measured HCV binding, intracellular levels of HCV RNA, and expression of target genes. We examined HCV entry in HepG2/microRNA (miR) 122/CD81 cells, which support entry and replication of HCV, were transfected these cells with small interfering RNAs targeting inhibitory SMADs to analyze gene expression profiles. Uptake of labeled low-density lipoprotein (LDL) and cholesterol was measured. Cell surface proteins were quantified by flow cytometry. We obtained liver biopsy samples from 69 patients with chronic HCV infection and 19 uninfected individuals (controls) and measured levels of syndecan 1 (SDC1), SMAD7, and SMAD6 messenger RNAs (mRNAs).
Small interfering RNA knockdown of SMAD6 blocked the binding and infection of hepatoma cell lines and primary human hepatocytes by HCV, whereas SMAD6 overexpression increased HCV infection. We found levels of mRNAs encoding heparan sulfate proteoglycans (HSPGs), particularly SDC1 mRNA, and cell surface levels of heparan sulfate to be reduced in cells after SMAD6 knockdown. SMAD6 knockdown also reduced transcription of genes encoding lipoprotein and cholesterol uptake receptors, including the LDL receptor (LDLR), the very LDLR, and the scavenger receptor class B member 1 in hepatocytes; knockdown of SMAD6 also inhibited cell uptake of cholesterol and lipoprotein. Overexpression of SMAD6 increased the expression of these genes. Similar effects were observed with knockdown and overexpression of SMAD7. In addition, HCV infection of cells increased the expression of SMAD6, which required the activity of nuclear factor-κB, but not transforming growth factor β. Liver tissues from patients with chronic HCV infection had significantly higher levels of SMAD6, SMAD7, and HSPG mRNAs than controls.
In studies of hepatoma cell lines and primary human hepatocytes, we found that infection with HCV leads to activation of nuclear factor-κB, resulting in increased expression of SMAD6 and SMAD7. Up-regulation of SMAD6 and SMAD7 induces the expression of HSPGs, such as SDC1, as well as LDLR, very LDLR, and the scavenger receptor class B member 1, which promote HCV entry and propagation, as well as cellular uptake of cholesterol and lipoprotein.
信号分子及转录调节因子SMAD6可抑制转化生长因子β信号通路,丙型肝炎病毒(HCV)感染肝细胞需要该因子。我们研究了SMAD6和另一种抑制性SMAD(SMAD7)促进HCV感染人肝癌细胞和肝细胞的机制。
我们用日本暴发性肝炎-1(JFH1)HCV细胞培养系统(HCVcc)感染Huh7和Huh7.5.1细胞以及原代人肝细胞。然后我们测量了HCV结合、HCV RNA的细胞内水平以及靶基因的表达。我们检测了HCV在支持HCV进入和复制的HepG2/微小RNA(miR)122/CD81细胞中的进入情况,用靶向抑制性SMAD的小干扰RNA转染这些细胞以分析基因表达谱。测量了标记的低密度脂蛋白(LDL)和胆固醇的摄取。通过流式细胞术对细胞表面蛋白进行定量。我们从69例慢性HCV感染患者和19例未感染个体(对照)获取肝活检样本,测量了Syndecan 1(SDC1)、SMAD7和SMAD6信使核糖核酸(mRNA)的水平。
SMAD6的小干扰RNA敲低阻断了HCV对肝癌细胞系和原代人肝细胞的结合与感染,而SMAD6过表达增加了HCV感染。我们发现,SMAD6敲低后,细胞中编码硫酸乙酰肝素蛋白聚糖(HSPG)的mRNA水平,特别是SDC1 mRNA水平以及硫酸乙酰肝素的细胞表面水平降低。SMAD6敲低还降低了肝细胞中编码脂蛋白和胆固醇摄取受体的基因的转录,包括LDL受体(LDLR)、极低密度脂蛋白受体和清道夫受体B类成员1;SMAD6敲低也抑制了细胞对胆固醇和脂蛋白的摄取。SMAD6过表达增加了这些基因的表达。SMAD7的敲低和过表达也观察到类似效果。此外,细胞的HCV感染增加了SMAD6的表达,这需要核因子κB的活性,但不需要转化生长因子β的活性。慢性HCV感染患者的肝组织中SMAD6、SMAD7和HSPG mRNA水平显著高于对照组。
在肝癌细胞系和原代人肝细胞的研究中,我们发现HCV感染导致核因子κB激活,从而导致SMAD6和SMAD7表达增加。SMAD6和SMAD7的上调诱导了HSPG(如SDC1)以及LDLR、极低密度脂蛋白受体和清道夫受体B类成员1的表达,这些促进了HCV的进入和传播以及细胞对胆固醇和脂蛋白的摄取。